Daniela Cullurà

431 total citations
21 papers, 322 citations indexed

About

Daniela Cullurà is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daniela Cullurà has authored 21 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Daniela Cullurà's work include Renal cell carcinoma treatment (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Daniela Cullurà is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Daniela Cullurà collaborates with scholars based in Italy, Switzerland and Canada. Daniela Cullurà's co-authors include Franco Nolè, Gaetano Aurilio, Roberto Iacovelli, Maria Cossu Rocca, Elena Verri, Matteo Santoni, Giuseppe Renne, Chiara Paglino, Stefano Cascinu and Camillo Porta and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Daniela Cullurà

21 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniela Cullurà Italy	8	205	193	99	76	62	21	322
Yingsheng Wen China	12	155 0.8×	145 0.8×	107 1.1×	94 1.2×	72 1.2×	27	323
Niels Viggo Jensen Denmark	11	234 1.1×	190 1.0×	99 1.0×	119 1.6×	101 1.6×	29	380
Swan‐Swan Leong Singapore	6	291 1.4×	246 1.3×	70 0.7×	108 1.4×	62 1.0×	7	461
Xianghui Du China	11	167 0.8×	154 0.8×	87 0.9×	83 1.1×	108 1.7×	27	353
M. Frueh Switzerland	9	189 0.9×	258 1.3×	43 0.4×	41 0.5×	38 0.6×	31	322
Yongling Ji China	11	130 0.6×	161 0.8×	63 0.6×	68 0.9×	93 1.5×	33	323
Anne-Claire Hardy-Bessard Spain	4	165 0.8×	130 0.7×	65 0.7×	38 0.5×	44 0.7×	5	296
Alessandra Ferro Italy	11	174 0.8×	183 0.9×	76 0.8×	79 1.0×	19 0.3×	37	315
Angelika Terbuch Austria	13	159 0.8×	172 0.9×	103 1.0×	149 2.0×	120 1.9×	33	397

Countries citing papers authored by Daniela Cullurà

Since Specialization

Citations

This map shows the geographic impact of Daniela Cullurà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Cullurà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Cullurà more than expected).

Fields of papers citing papers by Daniela Cullurà

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Cullurà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Cullurà. The network helps show where Daniela Cullurà may publish in the future.

Co-authorship network of co-authors of Daniela Cullurà

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Cullurà. A scholar is included among the top collaborators of Daniela Cullurà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Cullurà. Daniela Cullurà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Antonuzzo, Lorenzo, Rosa Tambaro, Sebastiano Buti, et al.. (2024). READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma. SHILAP Revista de lepidopterología. 5. 100068–100068. 4 indexed citations

Bracarda, Sergio, Lorenzo Antonuzzo, Marco Maruzzo, et al.. (2024). Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology. 42(4_suppl). 558–558. 5 indexed citations

Aurilio, Gaetano, Giovanni Mauri, D Rossi, et al.. (2023). Image-Guided Ablations in Patients with Recurrent Renal Cell Carcinoma. Journal of Clinical Medicine. 12(15). 4902–4902. 3 indexed citations

Musi, Gennaro, Francesco Alessandro Mistretta, Mattia Luca Piccinelli, et al.. (2023). Penile-Sparing Surgery for Tumour Recurrence after Previous Glansectomy/Partial Penectomy: Treatment Feasibility and Oncological Outcomes. Cancers. 15(19). 4807–4807. 2 indexed citations

Antonuzzo, Lorenzo, Marco Maruzzo, Ugo De Giorgi, et al.. (2023). READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology. 41(6_suppl). 469–469. 7 indexed citations

Aurilio, Gaetano, Elena Verri, Samuele Frassoni, et al.. (2020). Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. American Journal of Clinical Oncology. 43(6). 381–387. 5 indexed citations

Iacovelli, Roberto, Elena Verri, Maria Cossu Rocca, et al.. (2016). Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Critical Reviews in Oncology/Hematology. 99. 324–331. 10 indexed citations

Iacovelli, Roberto, Elena Verri, Maria Cossu Rocca, et al.. (2016). Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Anti-Cancer Drugs. 28(2). 206–212. 10 indexed citations

Nolè, Franco, Roberto Iacovelli, Elena Verri, et al.. (2015). Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Annals of Oncology. 26. vi57–vi57. 4 indexed citations

10.

Iacovelli, Roberto, Franco Nolè, Elena Verri, et al.. (2015). Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Targeted Oncology. 11(2). 143–148. 147 indexed citations

11.

Aurilio, Gaetano, Vincenzo Bagnardi, Franco Nolè, et al.. (2015). Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. Clinical Breast Cancer. 15(5). e237–e241. 13 indexed citations

12.

Iacovelli, Roberto, Elena Verri, Maria Cossu Rocca, et al.. (2015). The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. European Journal of Cancer. 51(14). 1970–1977. 33 indexed citations

13.

Nolè, Franco, Gaetano Aurilio, Roberto Iacovelli, et al.. (2015). 2649 Prognostic role of PD-L1 expression in renal cell carcinoma (RCC): A systematic review and meta-analysis. European Journal of Cancer. 51. S530–S530. 1 indexed citations

14.

Aurilio, Gaetano, Elisabetta Munzone, Edoardo Botteri, et al.. (2012). Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. The Breast Journal. 18(5). 470–474. 28 indexed citations

15.

Espósito, Angela, Elisabetta Munzone, Vincenzo Bagnardi, et al.. (2012). Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?. Anti-Cancer Drugs. 23(10). 1089–1098. 6 indexed citations

16.

Aurilio, Gaetano, Angela Sciandivasci, Elisabetta Munzone, et al.. (2011). First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial.. Journal of Clinical Oncology. 29(15_suppl). e11547–e11547. 1 indexed citations

17.

Cortinovis, Diego, Paolo Bidoli, Daniela Cullurà, et al.. (2008). Is Irinotecan Plus Docetaxel Useful as Second-Line Therapy in Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology. 3(4). 405–411. 2 indexed citations

18.

Bidoli, Paolo, Nicoletta Zilembo, Diego Cortinovis, et al.. (2006). Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Annals of Oncology. 18(3). 461–467. 28 indexed citations

19.

Bidoli, Paolo, Diego Cortinovis, L. Isa, et al.. (2005). Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin + gemcitabine (CBDCA + GEM), or oxaliplatin (L-OHP) + GEM, or sequential CBDCA + GEM→ docetaxel (DCT) + GEM in chemo-naive patients (pts) with advanced/metastatic non small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7118–7118. 4 indexed citations

20.

Arosio, Beatrice, et al.. (1994). Gene expression for interleukin-2 and tumor necrosis factor-alpha in the spleen of old rats under physiological condition and during septic shock. Possible pharmacological modulation.. PubMed. 44(12A). 1433–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact